Main Research and Development Centers
Each of our R&D centers specializes in a different area of scientific exploration. We have several major campuses located throughout the U.S. and U.K.
Andover, Massachusetts
Combining state-of-the-art R&D and Pfizer Global Supply (PGS) facilities with flexible, multi-product manufacturing capabilities, Andover is a key driver of innovation across our biologics discovery, development, and global clinical and commercial supply efforts.
Bothell, WA
Utilizing advanced laboratories and equipment, researchers in Bothell are dedicated to revolutionizing cancer treatment.
Cambridge, Massachusetts
Located in Kendall Square, our Cambridge site interlaces Pfizer’s R&D capability with the densest biomedical community in the world.
Groton, Connecticut
Many of the discoveries and innovations that drive the Pfizer pipeline to new potential occur in the world-class research and development laboratories in Groton.
San Diego, CA
With more than 500,000 square feet of state-of-the-art facilities, this is where our scientists discover and develop cutting-edge cancer therapies using advanced laboratories and equipment.
Pearl River, New York
As the global hub for Pfizer Vaccine Research and Development, our Pearl River colleagues have developed and manufactured vaccines and other medicines for more than a century.
St. Louis, MO
An expansive laboratory and manufacturing space, our colleagues focus on the development of potential new medicines to help prevent or treat diseases and conditions.

Clinical Trials
Learn more about the process of joining a clinical trial and find a trial near you.
Go to Pfizer Clinical Trials Site DetailsRelated Articles
September Social Media Round-Up—Prostate Cancer Awareness, TIME Executives of the Year, and More
As we enter fall, the days are getting shorter and the nights are getting cooler, but Pfizer’s social media channels are as active as ever.
Bourla at Concordia: The Business of Better Health
At the 2026 Concordia Annual Summit, Albert Bourla joined that conversation via a mainstage discussion with Alice Park, senior health correspondent at TIME, titled "The Business of Better Health."
How AI Is Helping Match Patients to Clinical Trials Faster
Before researchers can determine whether a potential new treatment is effective, they have to find enough eligible volunteers willing and able to participate in a trial. This process represents one of the biggest challenges in drug development.










